These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 19608672

  • 1. Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project.
    Giraldo P, Alfonso P, Atutxa K, Fernández-Galán MA, Barez A, Franco R, Alonso D, Martin A, Latre P, Pocovi M.
    Haematologica; 2009 Dec; 94(12):1771-5. PubMed ID: 19608672
    [Abstract] [Full Text] [Related]

  • 2. Twelve years of experience with miglustat in the treatment of type 1 Gaucher disease: The Spanish ZAGAL project.
    Giraldo P, Andrade-Campos M, Alfonso P, Irun P, Atutxa K, Acedo A, Barez A, Blanes M, Diaz-Morant V, Fernández-Galán MA, Franco R, Gil-Cortes C, Giner V, Ibañez A, Latre P, Loyola I, Luño E, Hernández-Martin R, Medrano-Engay B, Puerta J, Roig I, de la Serna J, Salamero O, Villalón L, Pocovi M.
    Blood Cells Mol Dis; 2018 Feb; 68():173-179. PubMed ID: 27836529
    [Abstract] [Full Text] [Related]

  • 3. Successful switch from enzyme replacement therapy to miglustat in an adult patient with type 1 Gaucher disease: a case report.
    Giuffrida G, Lombardo R, Di Francesco E, Parrinello L, Di Raimondo F, Fiumara A.
    J Med Case Rep; 2016 Nov 08; 10(1):315. PubMed ID: 27821156
    [Abstract] [Full Text] [Related]

  • 4. An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment.
    Pastores GM, Barnett NL, Kolodny EH.
    Clin Ther; 2005 Aug 08; 27(8):1215-27. PubMed ID: 16199246
    [Abstract] [Full Text] [Related]

  • 5. Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease.
    Elstein D, Hollak C, Aerts JM, van Weely S, Maas M, Cox TM, Lachmann RH, Hrebicek M, Platt FM, Butters TD, Dwek RA, Zimran A.
    J Inherit Metab Dis; 2004 Aug 08; 27(6):757-66. PubMed ID: 15505381
    [Abstract] [Full Text] [Related]

  • 6. Switching from imiglucerase to miglustat for the treatment of French patients with Gaucher disease type 1: a case series.
    Serratrice C, Swiader L, Serratrice J.
    J Med Case Rep; 2015 Jun 23; 9():146. PubMed ID: 26100396
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 Gaucher disease: a prospective, open-label non-inferiority study.
    Cox TM, Amato D, Hollak CE, Luzy C, Silkey M, Giorgino R, Steiner RD, Miglustat Maintenance Study Group.
    Orphanet J Rare Dis; 2012 Dec 27; 7():102. PubMed ID: 23270487
    [Abstract] [Full Text] [Related]

  • 8. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement.
    Elstein D, Dweck A, Attias D, Hadas-Halpern I, Zevin S, Altarescu G, Aerts JF, van Weely S, Zimran A.
    Blood; 2007 Oct 01; 110(7):2296-301. PubMed ID: 17609429
    [Abstract] [Full Text] [Related]

  • 9. Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies.
    Pastores GM, Elstein D, Hrebícek M, Zimran A.
    Clin Ther; 2007 Aug 01; 29(8):1645-54. PubMed ID: 17919546
    [Abstract] [Full Text] [Related]

  • 10. Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme.
    Hollak CE, Hughes D, van Schaik IN, Schwierin B, Bembi B.
    Pharmacoepidemiol Drug Saf; 2009 Sep 01; 18(9):770-7. PubMed ID: 19507165
    [Abstract] [Full Text] [Related]

  • 11. Short-term effect of miglustat in every day clinical use in treatment-naïve or previously treated patients with type 1 Gaucher's disease.
    Giraldo P, Latre P, Alfonso P, Acedo A, Alonso D, Barez A, Corrales A, Franco R, Roldan V, Serrano S, Pocovi M.
    Haematologica; 2006 May 01; 91(5):703-6. PubMed ID: 16627252
    [Abstract] [Full Text] [Related]

  • 12. Substrate reduction therapy with miglustat for type 1 Gaucher disease: a retrospective analysis from a single institution.
    Machaczka M, Hast R, Dahlman I, Lerner R, Klimkowska M, Engvall M, Hägglund H.
    Ups J Med Sci; 2012 Mar 01; 117(1):28-34. PubMed ID: 22247978
    [Abstract] [Full Text] [Related]

  • 13. Results from a 9-year Intensive Safety Surveillance Scheme (IS(3) ) in miglustat (Zavesca(®) )-treated patients.
    Brand M, Muller A, Alsop J, van Schaik IN, Bembi B, Hughes D.
    Pharmacoepidemiol Drug Saf; 2015 Mar 01; 24(3):329-33. PubMed ID: 25656910
    [Abstract] [Full Text] [Related]

  • 14. Randomized, controlled trial of miglustat in Gaucher's disease type 3.
    Schiffmann R, Fitzgibbon EJ, Harris C, DeVile C, Davies EH, Abel L, van Schaik IN, Benko W, Timmons M, Ries M, Vellodi A.
    Ann Neurol; 2008 Nov 01; 64(5):514-22. PubMed ID: 19067373
    [Abstract] [Full Text] [Related]

  • 15. Computerized cognitive testing in patients with type I Gaucher disease: effects of enzyme replacement and substrate reduction.
    Elstein D, Guedalia J, Doniger GM, Simon ES, Antebi V, Arnon Y, Zimran A.
    Genet Med; 2005 Feb 01; 7(2):124-30. PubMed ID: 15714080
    [Abstract] [Full Text] [Related]

  • 16. Combined miglustat and enzyme replacement therapy in two patients with type 1 Gaucher disease: two case reports.
    Amato D, Patterson MA.
    J Med Case Rep; 2018 Jan 27; 12(1):19. PubMed ID: 29373994
    [Abstract] [Full Text] [Related]

  • 17. Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients.
    Smid BE, Ferraz MJ, Verhoek M, Mirzaian M, Wisse P, Overkleeft HS, Hollak CE, Aerts JM.
    Orphanet J Rare Dis; 2016 Mar 24; 11():28. PubMed ID: 27008851
    [Abstract] [Full Text] [Related]

  • 18. Gastrointestinal disturbances and their management in miglustat-treated patients.
    Belmatoug N, Burlina A, Giraldo P, Hendriksz CJ, Kuter DJ, Mengel E, Pastores GM.
    J Inherit Metab Dis; 2011 Oct 24; 34(5):991-1001. PubMed ID: 21779792
    [Abstract] [Full Text] [Related]

  • 19. Miglustat therapy in type 1 Gaucher disease: clinical and safety outcomes in a multicenter retrospective cohort study.
    Kuter DJ, Mehta A, Hollak CE, Giraldo P, Hughes D, Belmatoug N, Brand M, Muller A, Schaaf B, Giorgino R, Zimran A.
    Blood Cells Mol Dis; 2013 Aug 24; 51(2):116-24. PubMed ID: 23683771
    [Abstract] [Full Text] [Related]

  • 20. Miglustat in late-onset Tay-Sachs disease: a 12-month, randomized, controlled clinical study with 24 months of extended treatment.
    Shapiro BE, Pastores GM, Gianutsos J, Luzy C, Kolodny EH.
    Genet Med; 2009 Jun 24; 11(6):425-33. PubMed ID: 19346952
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.